🎉 M&A multiples are live!
Check it out!

Oramed Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oramed Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Oramed Pharmaceuticals Overview

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.


Founded

2002

HQ

United States of America
Employees

13

Website

oramed.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$48.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Oramed Pharmaceuticals Financials

Oramed Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Oramed Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.9M.

Oramed Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Oramed Pharmaceuticals valuation multiples based on analyst estimates

Oramed Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.3M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA $7.3M -$14.9M XXX XXX XXX
EBITDA Margin 546% -Infinity% XXX XXX XXX
Net Profit -$36.6M $5.5M XXX XXX XXX
Net Margin -2728% Infinity% XXX XXX XXX
Net Debt n/a $42.0M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Oramed Pharmaceuticals Stock Performance

As of April 15, 2025, Oramed Pharmaceuticals's stock price is $2.

Oramed Pharmaceuticals has current market cap of $92.7M, and EV of -$48.8M.

See Oramed Pharmaceuticals trading valuation data

Oramed Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$48.8M $92.7M XXX XXX XXX XXX $-0.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Oramed Pharmaceuticals Valuation Multiples

As of April 15, 2025, Oramed Pharmaceuticals has market cap of $92.7M and EV of -$48.8M.

Oramed Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Oramed Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Oramed Pharmaceuticals and 10K+ public comps

Oramed Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$48.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 3.3x XXX XXX XXX
P/E -4.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 5.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oramed Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Oramed Pharmaceuticals Valuation Multiples

Oramed Pharmaceuticals's NTM/LTM revenue growth is n/a

Oramed Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Oramed Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Oramed Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Oramed Pharmaceuticals and other 10K+ public comps

Oramed Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -303% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Oramed Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Oramed Pharmaceuticals M&A and Investment Activity

Oramed Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Oramed Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Oramed Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Oramed Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Oramed Pharmaceuticals

When was Oramed Pharmaceuticals founded? Oramed Pharmaceuticals was founded in 2002.
Where is Oramed Pharmaceuticals headquartered? Oramed Pharmaceuticals is headquartered in United States of America.
How many employees does Oramed Pharmaceuticals have? As of today, Oramed Pharmaceuticals has 13 employees.
Who is the CEO of Oramed Pharmaceuticals? Oramed Pharmaceuticals's CEO is Mr. Nadav Kidron.
Is Oramed Pharmaceuticals publicy listed? Yes, Oramed Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Oramed Pharmaceuticals? Oramed Pharmaceuticals trades under ORMP ticker.
When did Oramed Pharmaceuticals go public? Oramed Pharmaceuticals went public in 2007.
Who are competitors of Oramed Pharmaceuticals? Similar companies to Oramed Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Oramed Pharmaceuticals? Oramed Pharmaceuticals's current market cap is $92.7M
Is Oramed Pharmaceuticals profitable? Yes, Oramed Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.